LSI

The ABCs of LSI USA ‘25 — Today’s letter of the day is C for Cybersecurity. In an increasingly digital Medtech landscape, cybersecurity has become a critical factor in regulatory success, market adoption, and patient trust. During this workshop, Christian Espinosa, Founder & CEO of Blue Goat Cyber, revealed how overlooked vulnerabilities can jeopardize FDA approval, delay clinical progress, and undermine credibility with investors. The session equipped attendees with actionable strategies to embed cybersecurity into every stage of product development—highlighting why it’s now a fundamental pillar, not a post-launch add-on. The video recordings of this workshop will be available in the coming weeks. Tune in each day as we recap LSI USA ‘25 from A to Z. PS: Registration is now open for LSI USA ‘26 next March 16-20 in Dana Point, California. Secure your spot early to take advantage of our best rates and have first priority for our hotel room block.

The ABCs of LSI USA ‘25 — Today’s letter of the day is C for CEO. On the final night of LSI USA ‘25, we hosted an exclusive CEO-Only Dinner, chaired by Bryan Lord, CEO of Pristine Surgical, to close the event with great food, drinks, and high-level conversation among fellow CEOs of emerging Medtech and Healthtech companies. We also hosted sessions focused on the unique challenges and transitions that come with leading a Medtech company. From building a strategy in the first 180 days to steering through periods of transition and change. These conversations offered practical frameworks and hard-won insights for CEOs navigating pivotal moments in their leadership journey. The CEO 180 Day Playbook ? Joe Mullings — Chairman & CEO, The Mullings Group ? Cason Kynes — Partner, Ajax Health ? Bernie Haffey — President & Founder, Haffey&Co.. ? Hanson Gifford — Managing Partner, The Foundry Navigating CEO Transitions — When, Why, and How to Make a Change ? David Krahe — Managing Director, Russell Reynolds Associates ? Mika Nishimura — Operational Partner, Gilde Healthcare ? Stuart Simpson — CEO, THINK Surgical ? Paul LaViolette — CEO, Pulse Biosciences, Inc. The video recordings of these sessions will be available in the coming weeks. Tune in each day as we recap LSI USA ‘25 from A to Z. PS: Registration is now open for LSI USA ‘26 next March 16-20 in Dana Point, California. Secure your spot early to take advantage of our best rates and have first priority for our hotel room block. #LSIUSA25

Hy2Care? BV (LSI Asia ‘25 Presenter) is a clinical phase company pursuing a breakthrough therapy with its CartRevive? hydrogel implant. The company’s vision is to support patients in the fight against osteoarthritis. Its lead product, CartRevive, is a hydrogel implant composed of dextran and hyaluronic acid conjugates that form a resorbable scaffold when injected. The hydrogel enables the natural restoration of tissue defects by creating an environment conducive to cell regrowth that proceeds toward the restoration of smooth hyaline cartilage. In October 2024, Hy2Care? completed its second clinical trial phase, treating the 46th patient with the CartRevive? hydrogel implant. This phase was approved by the Medical Ethical Review Committee of UMC Utrecht following the successful completion of an initial safety group of 10 patients, which began in 2022. The second phase of the clinical trial was conducted in collaboration with Dutch hospitals UMC Utrecht, Elisabeth-TweeSteden Ziekenhuis (ETZ), Maastricht UMC+, and Martini Hospital Groningen. At the end of 2024, Hy2Care? submitted an Investigational Device Exemption (IDE), marking an important step in its preparations to enter the US market. The first patient treatment is expected in early 2026, aligning with Hy2Care’s European goals, as CE marking is also anticipated by that time. Join us in welcoming Leo Smit, CEO of Hy2Care to LSI Asia ’25, where he’ll be presenting the company’s latest updates. Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are now open. Secure your spot today to join us at LSI Asia ‘25 on June 10th-13th at The Ritz-Carlton, Millenia Singapore.

The ABCs of LSI USA ‘25 — Today’s letter of the day is C for Clinical Trials. These sessions dove into the evolving clinical trial landscape—where rising costs, global complexity, and digital innovation are reshaping how trials are designed, executed, and scaled. Experts shared practical advice on avoiding costly missteps, choosing the right tech partners, and building smarter strategies for trial management in an increasingly demanding environment. Avoiding Critical Mistakes — How to Select the Right Clinical Trial Technology Partner ? Jill Hadel — Solutions Consultant II, Medidata Solutions ? Debbie Anderson — Managing Partner, Enterprise Sales, Medidata Solutions Managing Clinical Trials Amidst Skyrocketing Costs — Study Design, Global Work, Partnerships, and More ? Jeff Chu — Co-Founder & Managing Director, Features Capital ? Denise N. Bronner, Ph.D. — Founder & CEO, Empactful Ventures, LLC ? Marc Jones — CEO, Executive Chairman, Altoida, Inc. ? Angela Paterson — Principal Consultant, CS Lifesciences The video recordings of these sessions will be available in the coming weeks. Tune in each day as we recap LSI USA ‘25 from A to Z. PS: Registration is now open for LSI USA ‘26 next March 16-20 in Dana Point, California. Secure your spot early to take advantage of our best rates and have first priority for our hotel room block. #LSIUSA25

The ABCs of LSI USA ‘25 — Today’s letter of the day is B for “Building a Winning Board — Hits and Misses” A strong board can be a startup’s greatest asset or its biggest challenge. This workshop unpacked the key traits of an effective board, common missteps to avoid, and how to build the right mix of expertise and leadership to drive success. This workshop featured: ? Nick Pachuda — Innovation & New Ventures, Precision Life Science Partners ? Tamir Meiri — Director, Venture Investments, Johnson & Johnson MedTech ? Rui Jing J. — Founder & CEO, Avisi Technologies ? Jeffrey O'Donnell Sr. — Managing General Partner, Runway Healthcare L.P. ? Stefan Fischer — Managing Partner, TVM Capital Life Science The video recordings of this workshop will be available in the coming weeks. Tune in each day as we recap LSI USA ‘25 from A to Z. PS: Registration is now open for LSI USA ‘26 next March 16-20 in Dana Point, California. Secure your spot early to take advantage of our best rates and have priority for our hotel room block.

What Makes Singapore the Right Place for LSI Asia ‘25? Singapore's rise as a leading startup ecosystem is nothing short of remarkable. It has risen to be on a similar footing as traditional powerhouses like Beijing, backed by a supportive government, prominent institutional investors, sovereign wealth funds, family offices, and high-net-worth individuals, and attractive tax and financial structures that inspire flexible and efficient innovation and investment activity. Singapore's Medtech sector is particularly noteworthy. The country's commitment to fostering a conducive environment for medical device development, innovation, and manufacturing is evident by its outsized production of locally-made medical devices that punch above their weight on the global stage. The synergy between public policy, private enterprise, and academic research has created a positive feedback loop to nurture startups and attract capital at scale. Often referred to as a “gateway” to Southeast Asia, Singapore's strategic location makes it an ideal hub for connecting executives across Asia with one another, and with our established global community built through our parallel events in the USA and Europe. And of course, in selecting a location, it is paramount that we stay true to our ethos and find a world-class venue where senior executives can do real business. The Ritz-Carlton, Millenia Singapore is an award-winning, five-star property with authentic Cantonese Michelin-star restaurants, panoramic views, spacious accommodations, and state-of-the-art meeting and AV facilities. We’re confident our guests won’t mind stopping by Republic Bar either, which ranks among one of Asia's 50 Best Bars. Read the full article, “From Our CEO: Going Global With LSI Asia’s Launch in Singapore,” for the full story: https://lnkd.in/gmshyzFj Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are open. Secure your spot today to join us at LSI Asia ‘25 on June 10th-13th at The Ritz-Carlton, Millenia Singapore.

The ABCs of LSI USA ‘25 — Today’s letter of the day is B for Build to Buy. These sessions took a hard look at the build-to-buy model—examining what it means to grow a company with acquisition as the endgame. Speakers shared insights on timing, alignment, and deal dynamics, while also confronting the realities of shifting market conditions, changing strategic priorities, and the risks that can derail even the best-laid plans. New Era — Build to Buys ? Joe Mullings — Chairman & CEO, The Mullings Group ? Ramin Mousavi — President, CEO & Board Director, CathWorks ? Andrew ElBardissi, MD — Partner, Deerfield Management ? Addie H. — 1955 Capital ? Josh Makower — Stanford Mussallem Center for Biodesign Runaway Brides: Build-to-Buys at the Altar of Consummation (a Guide to Reinsurance Dating) ? Christopher Cleary — CEO, Biomergence Capital ? Hanson Gifford — Managing Partner, The Foundry and Partner, Lightstone Ventures ? Andrew Cleeland — CEO, Fogarty Innovation Signature Series: To Build or To Buy? Stryker's Thesis for AI, Robotics, and Organic vs Inorganic Growth ? Spencer Stiles, Group President, Orthopaedics and Spine at Stryker ? Moderated by Emily West, Managing Director at Goldman Sachs The video recordings of these sessions will be available in the coming weeks. Tune in each day as we recap LSI USA ‘25 from A to Z. PS: Registration is now open for LSI USA ‘26 next March 16-20 in Dana Point, California. Secure your spot early to take advantage of our best rates and have first priority for our hotel room block. #LSIUSA25

Biorithm (LSI Asia ‘25 Presenter) has a mission to end preventable pregnancy complications while reshaping how pregnancy care is delivered. The company is developing a comprehensive maternity care platform, Femom, to improve perinatal outcomes. The Femom platform merges clinical-grade fetal monitor data with patient reported symptoms and more traditional biometrics (e.g., glucose, blood pressure) to provide clinicians with new insights into the health of the mother and baby. Biorithm has reached significant milestones, including: ? Raised a $3.5M in Series A1 funding round co-led by Adaptive Capital Partners and SEEDS Capital (December 2023) ? Appointed Jenny Hoffmann, PhD as CEO (July 2024) ? Has four papers published in Tier 1 journals ? Two ongoing home-based studies in the US and UK to demonstrate a new maternity care standard. ? Currently has 600 patients enrolled worldwide To dive deeper into Biorithm’s mission and innovation, watch CEO, Jenny Hoffman’s LSI Europe ‘24 presentation on our website and YouTube channel. You can also connect with Founder Amrish Nair directly at LSI Asia '25 where he’s been selected to present Biorithm. Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are now open. Secure your spot today to join us at LSI Asia ‘25 on June 10th-13th at The Ritz-Carlton, Millenia Singapore.

The decision to launch LSI Asia is a response to the evolving dynamics of the global Medtech industry and our growing global community. Over the past few years, we have witnessed the Asia Pacific region emerge as a hotbed for innovation, capital, manufacturing, and business development. We’ve seen a shift from “me too” plays in the region to globally consequential innovation at the forefront of Deep Tech, Robotics, AI, and more. Chronic diseases like diabetes, cardiovascular diseases, cancers, and diseases of aging are driving policy, necessitating investment, and seeding a vibrant startup ecosystem. LSI’s Market Intelligence team even projects that China will surpass the United States in the total volume of tracked surgical procedures in 2024, with four of the five fastest-growing countries in total volume being in Asia (China, India, South Korea, and Singapore). This region is no longer just an emerging player; it is a critical driver of global Medtech growth. For executives operating outside of Asia, the region represents a "next frontier." Asia is characterized by a rapidly growing ecosystem of medical device startups, significant LP and investment activity, and the presence of major strategic players. This convergence of factors makes it the perfect time to establish a dedicated platform that caters to the unique needs and opportunities in the region, showcases both local and global innovation, and facilitates strategic partnerships domestically and across borders. Read the full article, “From Our CEO: Going Global With LSI Asia’s Launch in Singapore,” for the full story: https://lnkd.in/gmshyzFj Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are open. Secure your spot today to join us at LSI Asia ‘25 on June 10th-13th at The Ritz-Carlton, Millenia Singapore.

The ABCs of LSI USA are back! Today our letter of the day is A for Artificial Intelligence (AI). Throughout the event, we had multiple sessions that dove into various topics and impacts of AI including: Signature Series: No Corporate Slides. Real Strategies and Resources to Deliver Purpose-Driven AI ? Armen Vidian — Founder & Managing Partner, Recode Ventures ? Anne Osdoit — CEO, Moon Surgical ? Gabriel Jones — Founder & CEO, Proprio Panel: The AI Business-Building Era — Unlocking New Levels of Speed in Product Development, GTM, and More ? Robert Fenton — Founder & CEO, Qualio ? ?? Jim Schwoebel — Co-Founder & CEO of Quome ? Rachna Dayal — Founder & Managing Partner, Sugati Ventures Panel: How Will AI Revolutionize Imaging and Cardiovascular Care? ? Armen Vidian — Founder & Managing Partner, Recode Ventures ? Jyoti Gera — CEO, Cardiovascular and Interventional Solutions, GE HealthCare ? Adrian Lam, CFA — CEO, CorVista? Health ? Daniel Hawkins — CEO, Vista.ai Workshop: AI Agents and Models — Today, and Tomorrow ? Amrit Panjabi — Digital Health, AI, and Healthcare Analyst, CB Insights ? Vishal Gulati — Founder and Managing Partner, Recode Ventures The video recordings of these sessions will be available in the coming weeks. Tune in each day as we recap LSI USA ‘25 from A to Z. PS: Registration is now open for LSI USA ‘26 next March 16-20 in Dana Point, California. Secure your spot early to take advantage of our best rates and have first priority for our hotel room block.